<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36083004</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Effects of PB-TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts.</ArticleTitle><Pagination><StartPage>1551</StartPage><EndPage>1564</EndPage><MedlinePgn>1551-1564</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51648</ELocationID><Abstract><AbstractText Label="OBJECTIVE">ALS is a rapidly progressive, fatal disorder caused by motor neuron degeneration, for which there is a great unmet therapeutic need. AMX0035, a combination of sodium phenylbutyrate (PB) and taurursodiol (TUDCA, TURSO), has shown promising results in early ALS clinical trials, but its mechanisms of action remain to be elucidated. Therefore, our goal was to obtain an unbiased landscape of the molecular effects of AMX0035 in ALS patient-derived cells.</AbstractText><AbstractText Label="METHODS">We investigated the transcriptomic and metabolomic profiles of primary skin fibroblasts from sporadic ALS patients and healthy controls (n&#x2009;=&#x2009;12/group) treated with PB, TUDCA, or PB-TUDCA combination (Combo). Data were evaluated with multiple approaches including differential gene expression and metabolite abundance, Gene Ontology and metabolic pathway analysis, weighted gene co-expression correlation analysis (WGCNA), and combined multiomics integrated analysis.</AbstractText><AbstractText Label="RESULTS">Combo changed many more genes and metabolites than either PB or TUDCA individually. Most changes were unique to Combo and affected the expression of genes involved in nucleocytoplasmic transport, unfolded protein response, mitochondrial function, RNA metabolism, and innate immunity. WGCNA showed significant correlations between ALS gene expression modules and clinical parameters that were abolished by Combo treatment.</AbstractText><AbstractText Label="INTERPRETATION">This study is the first to explore the molecular effects of Combo in ALS patient-derived cells. It shows that Combo has a greater and distinct impact compared with the individual compounds and provides clues to drug targets and mechanisms of action, which may underlie the benefits of this investigational drug combination.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fels</LastName><ForeName>Jasmine A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, 407 East 61st Street, New York, New York, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Weill Cornell Graduate School of Medical Sciences, 1300 York Ave, New York, New York, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dash</LastName><ForeName>Jalia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, 407 East 61st Street, New York, New York, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leslie</LastName><ForeName>Kent</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Amylyx Pharmaceuticals, 43 Thorndike Street, Cambridge, Massachusetts, 02141, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3893-1348</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, 407 East 61st Street, New York, New York, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamata</LastName><ForeName>Hibiki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, 407 East 61st Street, New York, New York, 10065, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS104520</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS122209</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance></Chemical><Chemical><RegistryNumber>516-35-8</RegistryNumber><NameOfSubstance UI="D013655">Taurochenodeoxycholic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>60EUX8MN5X</RegistryNumber><NameOfSubstance UI="C031655">ursodoxicoltaurine</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013655" MajorTopicYN="N">Taurochenodeoxycholic Acid</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>This work was supported in part by a sponsored research agreement with Amylyx Pharmaceuticals. At the time when the work was performed, KL was employed by Amylyx.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>8</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36083004</ArticleId><ArticleId IdType="pmc">PMC9539390</ArticleId><ArticleId IdType="doi">10.1002/acn3.51648</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehta P, Raymond J, Punjani R, et&#xa0;al. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener. 2021;23:1&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34423697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al&#x2010;Chalabi A, Chio A, et&#xa0;al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;5(3):17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918&#x2010;1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et&#xa0;al. Trial of sodium phenylbutyrate&#x2010;Taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2010;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et&#xa0;al. Long&#x2010;term survival of participants in the CENTAUR trial of sodium phenylbutyrate&#x2010;taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Watkins C, Cawson M, et&#xa0;al. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve. 2022;66:136&#x2010;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9540225</ArticleId><ArticleId IdType="pubmed">35508892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusaczuk M. Tauroursodeoxycholate&#x2010;bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives. Cell. 2019;8(12):1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6952947</ArticleId><ArticleId IdType="pubmed">31757001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava P, Smith MD, Mische L, et&#xa0;al. Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. J Clin Invest. 2020;130(7):3467&#x2010;3482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324171</ArticleId><ArticleId IdType="pubmed">32182223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangerolamo L, Vettorazzi JF, Rosa LRO, Carneiro EM, Barbosa HCL. The bile acid TUDCA and neurodegenerative disorders: an overview. Life Sci. 2021;272:119252.</Citation><ArticleIdList><ArticleId IdType="pubmed">33636170</ArticleId></ArticleIdList></Reference><Reference><Citation>Launay N, Ruiz M, Grau L, et&#xa0;al. Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X&#x2010;linked adrenoleukodystrophy. Acta Neuropathol. 2017;133(2):283&#x2010;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5250669</ArticleId><ArticleId IdType="pubmed">28004277</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca I, Gordino G, Moreira S, et&#xa0;al. Tauroursodeoxycholic acid protects against mitochondrial dysfunction and cell death via mitophagy in human neuroblastoma cells. Mol Neurobiol. 2017;54(8):6107&#x2010;6119.</Citation><ArticleIdList><ArticleId IdType="pubmed">27699602</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant SM, DeMorrow S. Bile acid signaling in neurodegenerative and neurological disorders. Int J Mol Sci. 2020;21(17):5982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503576</ArticleId><ArticleId IdType="pubmed">32825239</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 2011;11(3):227&#x2010;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586072</ArticleId><ArticleId IdType="pubmed">21902286</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter DH. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res. 2002;52(6):832&#x2010;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">12438657</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WY, Bailey EC, McCune SL, Dong JY, Townes TM. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA. 1997;94(11):5798&#x2010;5803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20860</ArticleId><ArticleId IdType="pubmed">9159154</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiberson NGL, Pineda A, Abramov D, et&#xa0;al. Mechanism&#x2010;based rescue of Munc18&#x2010;1 dysfunction in varied encephalopathies by chemical chaperones. Nat Commun. 2018;9(1):3986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6162227</ArticleId><ArticleId IdType="pubmed">30266908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb PS, Ayaub EA, Zhou W, Yum V, Dickhout JG, Ask K. The therapeutic effects of 4&#x2010;phenylbutyric acid in maintaining proteostasis. Int J Biochem Cell Biol. 2015;61:45&#x2010;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25660369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H, Smith K, Camelo SI, et&#xa0;al. Sodium phenylbutyrate prolongs survival and regulates expression of anti&#x2010;apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93(5):1087&#x2010;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">15934930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K, Gennings C, Hupf JC, et&#xa0;al. Bioenergetic markers in skin fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral sclerosis patients. Ann Neurol. 2014;76(4):620&#x2010;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192005</ArticleId><ArticleId IdType="pubmed">25090982</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C, Kawamata H, Bredvik KG, et&#xa0;al. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol Neurodegener. 2017;12(1):76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655870</ArticleId><ArticleId IdType="pubmed">29065921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Konrad C, Sandhu D, et&#xa0;al. Accelerated transsulfuration metabolically defines a discrete subclass of amyotrophic lateral sclerosis patients. Neurobiol Dis. 2020;144:105025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491150</ArticleId><ArticleId IdType="pubmed">32745521</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R, Allen SP, Goodall EF, et&#xa0;al. Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia&#x2010;response and RNA processing functions. Neuropathol Appl Neurobiol. 2015;41(2):201&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329387</ArticleId><ArticleId IdType="pubmed">24750211</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat&#x2010;Durebex C, Bris C, Codron P, et&#xa0;al. Metabo&#x2010;lipidomics of fibroblasts and mitochondrial&#x2010;endoplasmic reticulum extracts from ALS patients shows alterations in purine, pyrimidine, energetic, and phospholipid metabolisms. Mol Neurobiol. 2019;56(8):5780&#x2010;5791.</Citation><ArticleIdList><ArticleId IdType="pubmed">30680691</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerou M, Hall B, Woof R, et&#xa0;al. Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts. Neurobiol Aging. 2021;105:64&#x2010;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8346650</ArticleId><ArticleId IdType="pubmed">34044197</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SP, Duffy LM, Shaw PJ, Grierson AJ. Altered age&#x2010;related changes in bioenergetic properties and mitochondrial morphology in fibroblasts from sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging. 2015;36(10):2893&#x2010;2903.</Citation><ArticleIdList><ArticleId IdType="pubmed">26344876</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Arozamena S, Lopez de Munain A. Dermic&#x2010;derived fibroblasts for the study of amyotrophic lateral sclerosis. Neural Regen Res. 2020;15(11):2043&#x2010;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716046</ArticleId><ArticleId IdType="pubmed">32394958</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Castanedo&#x2010;Vazquez D, Gil&#x2010;Bea F, et&#xa0;al. ALS&#x2010;derived fibroblasts exhibit reduced proliferation rate, cytoplasmic TDP&#x2010;43 aggregation and a higher susceptibility to DNA damage. J Neurol. 2020;267(5):1291&#x2010;1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">31938860</ArticleId></ArticleIdList></Reference><Reference><Citation>Debska&#x2010;Vielhaber G, Miller I, Peeva V, et&#xa0;al. Impairment of mitochondrial oxidative phosphorylation in skin fibroblasts of SALS and FALS patients is rescued by in&#xa0;vitro treatment with ROS scavengers. Exp Neurol. 2021;339:113620.</Citation><ArticleIdList><ArticleId IdType="pubmed">33497646</ArticleId></ArticleIdList></Reference><Reference><Citation>Manberg A, Skene N, Sanders F, et&#xa0;al. Altered perivascular fibroblast activity precedes ALS disease onset. Nat Med. 2021;27(4):640&#x2010;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA&#x2010;seq data with DESeq2. Genome Biol. 2014;15(12):550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 2009;37(Web Server issue):W652&#x2010;W660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703878</ArticleId><ArticleId IdType="pubmed">19429898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Hu E, Xu S, et&#xa0;al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2(3):100141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8454663</ArticleId><ArticleId IdType="pubmed">34557778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Z, Chong J, Zhou G, et&#xa0;al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49(W1):W388&#x2010;W396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8265181</ArticleId><ArticleId IdType="pubmed">34019663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohart F, Gautier B, Singh A, Le Cao KA. mixOmics: an R package for 'omics feature selection and multiple data integration. PLoS Comput Biol. 2017;13(11):e1005752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5687754</ArticleId><ArticleId IdType="pubmed">29099853</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca SG, Ishigaki S, Oslowski CM, et&#xa0;al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest. 2010;120(3):744&#x2010;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827948</ArticleId><ArticleId IdType="pubmed">20160352</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampieri L, Di Giusto P, Alvarez C. CREB3 transcription factors: ER&#x2010;Golgi stress transducers as hubs for cellular homeostasis. Front Cell Dev Biol. 2019;7:123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6616197</ArticleId><ArticleId IdType="pubmed">31334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallotta MT, Tascini G, Crispoldi R, et&#xa0;al. Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med. 2019;17(1):238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6651977</ArticleId><ArticleId IdType="pubmed">31337416</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M, van Blitterswijk MM, Vlam L, et&#xa0;al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(4):837 e7&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">22078486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrington DA, Gregerson DS. Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci. 2012;109:75&#x2010;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405001</ArticleId><ArticleId IdType="pubmed">22727420</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA. RNA dysregulation in amyotrophic lateral sclerosis. Front Genet. 2018;9:712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381&#x2010;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193420</ArticleId><ArticleId IdType="pubmed">21321607</ArticleId></ArticleIdList></Reference><Reference><Citation>Besnard A, Galan&#x2010;Rodriguez B, Vanhoutte P, Caboche J. Elk&#x2010;1 a transcription factor with multiple facets in the brain. Front Neurosci. 2011;5:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060702</ArticleId><ArticleId IdType="pubmed">21441990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Song X, Herrup K. Context&#x2010;dependent functions of E2F1: cell cycle, cell death, and DNA damage repair in cortical neurons. Mol Neurobiol. 2020;57(5):2377&#x2010;2390.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062842</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006;13(2):115&#x2010;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2455793</ArticleId><ArticleId IdType="pubmed">16138117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H, Lee J, Zaman K, et&#xa0;al. Sp1 and Sp3 are oxidative stress&#x2010;inducible, antideath transcription factors in cortical neurons. J Neurosci. 2003;23(9):3597&#x2010;3606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742168</ArticleId><ArticleId IdType="pubmed">12736330</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifert LL, Si C, Saha D, et&#xa0;al. The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response. PLoS Pathog. 2019;15(11):e1007634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6932815</ArticleId><ArticleId IdType="pubmed">31682641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Shi Y, Mulligan P, et&#xa0;al. A YY1&#x2010;INO80 complex regulates genomic stability through homologous recombination&#x2010;based repair. Nat Struct Mol Biol. 2007;14(12):1165&#x2010;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754171</ArticleId><ArticleId IdType="pubmed">18026119</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YZ, Bennett CL, Huynh HM, et&#xa0;al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74(6):1128&#x2010;1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182077</ArticleId><ArticleId IdType="pubmed">15106121</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Horvath S. A general framework for weighted gene co&#x2010;expression network analysis. Stat Appl Genet Mol Biol 2005;4:Article17. doi:10.2202/1544-6115.1128</Citation><ArticleIdList><ArticleId IdType="doi">10.2202/1544-6115.1128</ArticleId><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JC, Ramaswami G, Geschwind DH. Gene co&#x2010;expression network analysis in human spinal cord highlights mechanisms underlying amyotrophic lateral sclerosis susceptibility. Sci Rep. 2021;11(1):5748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7970949</ArticleId><ArticleId IdType="pubmed">33707641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreelatha A, Yee SS, Lopez VA, et&#xa0;al. Protein AMPylation by an evolutionarily conserved Pseudokinase. Cell. 2018;175(3):809&#x2010;21.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524645</ArticleId><ArticleId IdType="pubmed">30270044</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin CS, Meng S, Garbis SD, et&#xa0;al. LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding. Nat Commun. 2021;12(1):265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801493</ArticleId><ArticleId IdType="pubmed">33431889</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams BM, Canniff NP, Guay KP, Larsen ISB, Hebert DN. Quantitative glycoproteomics reveals cellular substrate selectivity of the ER protein quality control sensors UGGT1 and UGGT2. Elife. 2020;9:e63997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7771966</ArticleId><ArticleId IdType="pubmed">33320095</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. Orai1 is an essential pore subunit of the CRAC channel. Nature. 2006;443(7108):230&#x2010;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921383</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemmer M, Forster F. A clearer picture of the ER translocon complex. J Cell Sci. 2020;133(3):1&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32019826</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia AE, Lalli S, Monsurro MR, et&#xa0;al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45&#x2010;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024041</ArticleId><ArticleId IdType="pubmed">25664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Andres PL, Macdonald SA, et&#xa0;al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10(2):99&#x2010;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">18688762</ArticleId></ArticleIdList></Reference><Reference><Citation>Serefidou M, Venkatasubramani AV, Imhof A. The impact of one carbon metabolism on histone methylation. Front Genet. 2019;10:764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6722216</ArticleId><ArticleId IdType="pubmed">31555321</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett SA, Tanaz R, Cobos SN, Torrente MP. Epigenetics in amyotrophic lateral sclerosis: a role for histone post&#x2010;translational modifications in neurodegenerative disease. Transl Res. 2019;204:19&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331271</ArticleId><ArticleId IdType="pubmed">30391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi EG, Thompson T, Li J, et&#xa0;al. Answer ALS, a large&#x2010;scale resource for sporadic and familial ALS combining clinical and multi&#x2010;omics data from induced pluripotent cell lines. Nat Neurosci. 2022;25(2):226&#x2010;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop PJ, Zwamborn RAJ, Hannon E, et&#xa0;al. Genome&#x2010;wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Sci Transl Med. 2022;14:eabj0264.</Citation><ArticleIdList><ArticleId IdType="pubmed">35196023</ArticleId></ArticleIdList></Reference><Reference><Citation>Giampetruzzi A, Danielson EW, Gumina V, et&#xa0;al. Modulation of Actin polymerization affects nucleocytoplasmic transport in multiple forms of amyotrophic lateral sclerosis. Nat Commun. 2019;10(1):3827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6707192</ArticleId><ArticleId IdType="pubmed">31444357</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Baskerville V, Zaepfel BL, et&#xa0;al. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP&#x2010;43 dysfunction in sporadic and familial ALS. Sci Transl Med. 2021;13(604):eabe1923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022198</ArticleId><ArticleId IdType="pubmed">34321318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Taylor JP. Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron. 2017;96(2):285&#x2010;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fels JA, Casalena G, Konrad C, Holmes HE, Dellinger RW, Manfredi G. Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301. Hum Mol Genet. 2022:1&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9558834</ArticleId><ArticleId IdType="pubmed">35652455</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>